Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241172EnglishN2025January28Healthcare Impact of Physical Activities on the Physical Constitution of Female Farmers, Cyclists, and Traders in Makoua, Republic of Congo English0107Alongo Yvon Rock GhislainEnglish Moussouami Innocent SimpliceEnglish Sompi FlorentEnglish Moukouyou Eric AntoineEnglish Itoua Onianguet Assoba KielEnglish Obela Ibata Gency Espoir ReussiteEnglish Introduction: Physical activity is an important determinant of health at all stages of life, but remains a modifiable behavior. In- creasingly, fortifying people to exercise is an investment in human capital that can generate multiple benefits, both for individuals and for communities. Aim/Objectives: The aim of this study was to assess the effects of physical activity on the body transformation of female farmer-cyclists and shopkeepers. Method: The study involved 63 participants divided into two groups: 31 female farmer-cyclists and 32 female traders from Makoua’s main market. Participants underwent an experiment assessing height, weight, body mass index and physical constitution variables before and after a 16-week period. Results: Revealed an exponential difference in anthropometric and physical constitution variables in favour of farmer-cyclists, particularly in terms of weight, total fat mass and visceral fat mass. However, data relating to muscle mass and physical capacity were also in favour of farmer-cyclists. Conclusion: Our results show that traders are more exposed to metabolic diseases. They should combine their commercial activities with physical activity, particularly cycling, to improve their body composition. EnglishPhysical activities, Body composition Farmers, Traders, Women, Makouahttp://ijcrr.com/abstract.php?article_id=4836http://ijcrr.com/article_html.php?did=4836 1. Taher AT, Weatherall DJ, Cappellini MD. Thalassemia. Lancet. 2022;395(10233):1413-1426. 2. Cohen AR, Porter JB. Transfusion-related iron overload: Clinical implications and strategies for management. Blood Rev. 2021; 47:100785. 3. Musallam KM, Rivella S, Viprakasit V, Kattamis A. Iron overload in non-transfusion-dependent thalassemia: Clinical implications and therapeutic strategies. Haematologica. 2023;108(1):42-57. 4. Angelucci E, Pilo F. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Hemoglobin. 2021;45(1):15-22. 5. Cappellini MD, Cohen A, Porter J. Guidelines for the management of transfusion dependent thalassemia (TDT), 4th edition. Thalassemia International Federation. 2021. 6. Porter JB, Shah FT. Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am. 2022;36(2):371- 389. 7. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusiondependent thalassemia major patients may prevent or reverse early cardiac dysfunction. Blood. 2021;116(18):3733-3740. 8. Yassin MA, Soliman AT, De Sanctis V. The impact of iron chelation adherence on morbidity and mortality in β-thalassemia major: A 10-year study. Acta Biomed. 2022; 93(1):e2022001. 9. Aydinok Y, Porter JB, Piga A. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: Results from the CORDELIA study. Eur J Haematol. 2023;110(1):31-40. 10. Pepe A, Meloni A, Pistoia L. MRI monitoring of iron overload in thalassemia major: multicentre validation of the T2* technique. Haematologica. 2022;107(8):1896-1906. 11. Cappellini MD, Porter JB, El-Beshlawy A, Li CK, Seymour JF, Elalfy M et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2023;95(4):557-566. 12. Porter JB, Evangeli M, El-Beshlawy A. Challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2021;94(5):453-460. 13. Sharma V, Piga A, Ghosh K. Long-term efficacy and safety of deferasirox in young children with transfusional haemosiderosis: Results from a 5-year observational study. Br J Haematol. 2022;173(1):103-111. 14. Lal A, Porter J, Sweeters N. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Adv. 2023;7(1):23-30. 15. Thompson AA, Kwiatkowski JL, Kim HY. Patient-reported outcomes in transfusion-dependent β-thalassemia patients receiving iron chelation therapy. Am J Hematol. 2023;98(2):167-175. 16. Chen H, Ataga KI, Caughey AB. Cost-effectiveness of iron chelation regimens in transfusion-dependent thalassemia major. Blood Adv. 2021;5(23):4851-4860. 17. Rodriguez MP, Grady RW, Hidalgo G. Iron chelation in thalassemia: combined or monotherapy? The recent evidence. Ann N Y Acad Sci. 2022; 1368:140-147. 18. Kumar R, Piga A, Khalil A. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional ironoverloaded patients with sickle cell disease. Br J Haematol. 2023;162(2):275-284. 19. Yang G, Liu R, Peng P. How iron overload patterns affect outcomes in patients with transfusion-dependent thalassemia: a cost-effectiveness analysis. Haematologica. 2023;108(3):729- 738.